Search Results
SOLO3 Reviews Potential Toxicities With Olaparib in Ovarian Cancer
Dr. Matulonis on Toxicities With Olaparib for Patients With Ovarian Cancer
Olaparib considerably increases PFS in ovarian cancer
Dr. Robson on the Toxicity Profile of Olaparib in Breast Cancer
Anne talks about ovarian cancer and drug olaparib
Dr. Penson on Research With PARP Inhibitors in Ovarian Cancer
Dr. Penson on the Eligibility Criteria for PARP Inhibitors in Advanced Ovarian Cancer
Dana Chase, MD, considers the role of PARP inhibitors in advanced ovarian cancer today
Olaparib + beva maintenance in newly diagnosed, advanced ovarian cancer (OC) treated with PCh + bev
Ongoing Clinical Trials with PARP Inhibitors in Ovarian Cancer
OlympiA: adjuvant olaparib following chemo significantly improves IDFS
Defining Rucaparib’s Value in Recurrent Ovarian Cancer
